ABSTRACT
INTRODUCTION
Systemic lupus erythematosus (SLE) is a systemic chronic inflammatory disorder characterized by a wide range of immunological hyperactivity, autoantibody production and multi-organ damages (1) . Women with SLE have been demonstrated to have 50-fold increased risk of developing myocardial infarction than women in general population. The relative risk for coronary heart disease has been still 7 to 17-fold higher, even after adjusting for traditional risk factors in SLE (2) . Therefore, these reports have suggested that patients with SLE possess excess risks over the traditional risk factors for the development of accelerated atherosclerosis, and these risk factors might be metabolic changes like lipoprotein oxidation, insulin resistance, hyperhomocysteinemia and vascular stiffness which may also significantly contribute to the pathogenesis of cardiovascular disease (3) .
Cytokines play an important and diverse role in the pathogenesis of lupus. There are a variety of hypothetical explanations for cytokine imbalances in that disease. Considerable attention has been given to the Th1/Th2 model as well as to combinations of pro-and antiinflammatory mediators (1) . Interferon-γ (IFN-γ) is the classic Th1 cytokine. Its expression is regulated by a number of IFNinducing monokines, such as IL-12, IL-18, and IL-15. Elevated serum levels of IL-12,IL-18,and IFN-γ have been observed in patients with active lupus (4) . Also, IL 18, make atherosclerotic lesions in SLE more prone to rupture than in 'normal' atherosclerosis (5) . Elevation of plasma concentration of total homocysteine (tHcy) is considered to be a clinical risk factor for cardiovascular disease (1-3) . Mild or moderate hyperhomocysteinemia (plasma tHcy concentration of 15 to 50 mmol/L) is found in up to 40% of patients with myocardial infarction, stroke, or venous thrombosis (6) , and it may contribute to the pathogenesis of cardiovascular diseases in SLE (7) .
Aim of work
To evaluate the relationship of interleukin 18 concentrations as well as SAH,SAM and SAM/SAH ratio to some cardiovascular risk factors in patients with Systemic Lupus Erythematosus (SLE) and to evaluate their possible clinical significance with the disease activity.
PATIENTS & METHODS
The current study was carried out on 31 patient with SLE (27 female and 4 males) selected from the Rheumatology and Immunology Outpatient and Inpatient Clinic at Mansoura University Hospitals, Internal Medicine Department. Thirty, sex-and age-matched healthy volunteers were recruited as controls.
All patients fulfilled four or more of the American College of Rheumatology revised criteria for diagnosis of SLE (8) . SLE patients with a history of diabetes mellitus, hypertension, hyperlipidemia, smoking, or coronary artery disease (CAD) and positive pregnancy test were excluded.
The systemic lupus disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). SLEDAI was developed by the consensus experts a global assessment of lupus disease activity. Points are based on a weighted index for lupus disease activity with 8 points for central nervous and vascular systems, 4 points for renal and musculoskeletal system, 2 points for serosal, dermal and immunological systems, 1 point for constitutional and hematologic parameters. The points are assigned if the descriptor is present at the time of the present visit or within the preceding 10 days. Mild to moderate disease is associated with SLEDAI scores ≤10 and SLEDAI scores >10 are associated with greater disease activity. In the present study any value above 4 was considered active disease (9) . Study subjects underwent full history taking and thorough physical examination. The BMI of each patient was calculated as the weight in kilograms divided by the square of height in meters. Blood pressure was measured, laboratory investigations: urine analysis.
Especially Carotid IMT of the common carotid artery was determined using duplex ultrasonography with a highresolution 7.5-MHz transducer (SSA-380A; Toshiba, Tokyo, Japan). Carotid IMT was defined as the distance from the leading edge of the first echogenic line to the leading edge of the second echogenic line in the sonographic image. Measurements of IMT were made at each of the three sites of the greatest thickness on both sides. Carotid IMT was defined as the mean of these maximal IMT measurements (20) .
Statistical analyses
Data were collected, revised, verified then edited on personal computer and then analyzed using the Statistical Package of Social Sciences (SPSS) version 10 for Windows (SPSS, Inc., Chicago, IL, USA). Data were presented using mean and standard deviation (SD) for all quantitative values and or number of cases (percentage) for qualitative values.
The distribution of tested variables was examined graphically for normality. Pearson's correlation analysis was used to examine the relationships between plasma IL-18 and tested cardiovascular risk factors. Receiver Operating Characteristic (ROC) graph analysis for plasma IL-18 and SAM/SAH ratio in order to quantitate and assess its diagnostic performance in differentiation between SLE patients and control subjects. P values <0.05 were considered significant for all statistical analyses in the present study.
RESULTS
The study populations comprised 31 patients with SLE with a mean age of 35.1±10.3 years and 30 control subjects with a mean age of 33.4±9.6 years. Patients with SLE and control subjects were well matched with respect to age, gender and BMI. The mean SLE disease duration was 4.2±2.9 years (range from 0.2 to 10 years).
The concentrations of plasma IL-18 in SLE patients were significantly higher than those in control subjects (222.6±66.5 pg/ml versus 133.4±44.2, p< 0.001).
The plasma concentration of SAM is statistically significantly lower in SLE patients than the control group(86.1±10.2 versus 116.1 ±26.9,p< 0.001), the plasma SAH concentration shows statistically significant increase in SLE patients than the controls(34.7±7.8 versus 23.8±6.9 ,p< 0.001),consequently the SAM/SAH ratio shows statistically significant decrease in SLE patients than the controls(2.65±0.94 versus 5.24 ±1.8 p< 0.001)( table ,1).
However, there was a significant positive correlation between IL-18 concentrations and SLEDAI score in SLE patients (r = 0.449, P = 0.004) (figure 2).
There were significant positive correlation between plasma IL-18 concentrations and body mass index (r= 0.45,p= 0.01), plasma levels of triglycerides (r=0.42,p=0.02), fasting insulin (r=0.54,p=0.002) and HOMA-IR (r= 0.52,p=0.003), CIMT (r=0.22,p= 0.04).
No significant correlation was found between IL-18 concentrations and other cardiovascular risk factors (table 2) .
There were significant positive correlation between plasma IL 18 concentrations and ANA (r=0.6,p=0.001), Anti dsDNA (r= 0.5, p=0.008), ESR1 (r= 0.56, p=0.001) and serum creatinine (r= 0.7, p=0.001) (table 3).
The concentrations of plasma IL-18 in SLE patients with elevated plasma creatinine were significantly higher than those with normal plasma creatinine (285.7.6±59.6 pg/ml versus 182.8±29.4, p< 0.001; 18.5±7.6 ųmol/l versus 12.8± 3.7, p< 0.001 respectively), while, SAM/SAH ratio was significantly lower in patients with elevated plasma creatinine than those with normal plasma creatinine.
CIMT was significantly greater in SLE patients than in control subjects (0.89 ± 0.42 vs. 0.59 ± 0.11 mm, P<0.0001) (table  1) . Plasma concentrations of IL-18 tended to correlate positively with mean CIMT (r = 0.22, P = 0.04) (table 2) .
There was positive correlations between systemic lupus erythematosus disease activity index and both plasma levels of insulin and HOMA-IR values (p<0.05 in both) (table 5) .
Also, there was positive statistically significant positive correlation between plasma SAH concentration and BMI, IL-18 and plasma creatinine level, but it showed significant negative correlation with HDL-C, and fasting blood glucose level (table 4) .
On the other hand, there was statistically significant negative correlation between plasma SAM concentration and triglycerides, IL-18, fasting plasma glucose and plasma creatinine level and there was significant negative correlation between SAM/SAH ratio and BMI, TG, HDL-C, IL-18, fasting blood glucose and plasma creatinine level. Figure 3 shows Receiver Operating Characteristic (ROC) graph analysis for plasma IL-18 and SAM/SAH ratio. The graph was applied in order to quantitate and assess its diagnostic performance in differentiation between SLE patients and control subjects. It revealed that the best cut off value of plasma IL-18 was 3.7 as the diagnostic sensitivity was 70.3 %, specificity of 90.3%. The area under the ROC curve was 0.83 (95% confidence interval 0.75-0.94, p=0.001) and SAM/SAH ratio was 3.7 as the diagnostic sensitivity was 80.0 %, specificity of 91.0%. The area under the ROC curve was 0.91 (95% confidence interval 0.80-0.97, p=0.001). 
DISCUSSION
The incidence of SLE appears to be increasing and the main cause of death in that disease is coronary artery disease and the risk of cardiovascular disease is very high in SLE patients (5) . SLE is a chronic inflammatory disease in which inflammatory and immune disease processes are likely to contribute to the accelerated atherosclerosis observed in that disease (21) . The present study was designed to evaluate the relationship of interleukin 18 concentrations as well as SAH,SAM and SAM/SAH ratio to some traditional and non traditional cardiovascular risk factors in patients with systemic lupus erythematosus (SLE) and to evaluate their possible clinical significance with the disease activity.
In the current study, the plasma concentrations of IL-18 were elevated in SLE patients compared with healthy controls. These results agreed with those of Tso et al. . That finding suggests that elevation of plasma IL-18 levels may not enhance lipid and lipoprotein oxidations in patients with SLE.
Circulating IL-18 concentrations were also increased in insulin resistance states as in type 2 diabetes mellitus individuals compared with those in controls (28) . In the present study, we also identified positive correlations of plasma IL-18 with insulin levels and HOMA-IR in patients with SLE. These results were in accordance with the results of Tso et al.
(3)
. That finding suggests that elevation of plasma IL-18 may, at least in part, link inflammation with hyperinsulinemia and/or insulin resistance in SLE patients.
The measurement of SAH, SAM and calculating SAM/SAH ratio is considered to be better biomarker of atherosclerosis than homocysteine measurement and may be causally linked to cardiovascular disease pathogenesis as reported by Liu et al. (29) who reported that SAH is elevated in cardiovascular diseases in population with extensive atherosclerosis.
In the present study, the elevated SAH level, the decreased level of SAM and SAM/SAH ratio in SLE patients compared with the healthy controls may be related to disturbed homocysteine metabolism among those patients and hyperhomocysteinemia is evident in SLE patients. This result is in harmony with that of Petri et al. (30) who stated that raised circulating homocysteine concentration is a risk factor for thrombotic and atherosclerotic disorders in SLE.
Homocysteine is the product of the intracellular methionine cycle, in which methionine is initially activated by ATP to S adenosylmethionine (SAM), the primary methyl donor for essential methyltransferase reaction. After methyl transfer, SAM is converted to S adenosylhomocysteine (SAH). The sole source of homocysteine in the body is the hydrolysis of SAH. The equilibrium dynamics favor the reverse reaction, the synthesis rather than the hydrolysis of SAH. Thus, elevated homocysteine concentration causes SAH accumulation (31) . Increased SAH is a potent product inhibitor of cellular methyltransferase which can alter gene expression, cell proliferation and apoptosis (32, 33 (36) as they stated that renal function is a strong determinant of the concentration of homocysteine, and both plasma creatinine and SAH are significantly different between patients and controls.
The analysis of IL-18 and SAM/SAH ratio has revealed both as two discriminating cardiovascular risk factors in patients with SLE versus controls with a criterion values > 157.3&< 3.7 respectively .These indicate that IL-18 and SAM/SAH ratio are useful biomarkers for cardiovascular risk in patients with SLE and that finding is in harmony with the results of Tso et al,
In the present study, the significant increase in SLE patients than in control subjects, and its positive correlation of IL-18 with CIMT may indicate that IL-18 may be involved in the development of vascular stiffness in patients with SLE. The same result was obtained by Leeuw et al.
(37) and Colombo et al. (38) who found that CIMT was higher in SLE patients than controls. In the present work, the negative correlation between SAM/SAH ratio with IL-18 and CIMT is an indicators that hyperhomocysteinemia was associated with increased secretion of IL-18 and increased thickness of the wall of carotid artery and these coincides with the result of Aso et al. 
